Levofloxacin, metronidazole, and lansoprazole triple therapy compared to quadruple therapy as a second-line treatment of helicobacter pylori infection in Korea

Gut and Liver

Volumn 7, Issue 4, 2013, Pages 406-410

  Moon, Ji Yoon ^a   Kim, Gwang Ha ^a   You, Hyun Seok ^b   Lee, Bong Eun ^a   Ryu, Dong Yeop ^a   Cheong, Jae Hoon ^a   Jung, Jung Im ^a   Jeong, Jae Hoon ^b   Song, Chul Soo ^c   Song, Geun Am ^a  

^a Pusan National University School of Medicine   (South Korea)

^b Busan Medical Center   (South Korea)

^c Good Samsun Hospital   (South Korea)

Author keywords

Failure; Helicobacter pylori; Levofloxacin; Metronidazole; Therapeutics

Indexed keywords

BISMUTH CITRATE; LANSOPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; TETRACYCLINE;

ABDOMINAL PAIN; ADULT; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; HEADACHE; HEARTBURN; HELICOBACTER INFECTION; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; METALLIC TASTE; NAUSEA; RANDOMIZED CONTROLLED TRIAL; TASTE DISORDER; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 84880256039     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl.2013.7.4.406     Document Type: Article

References (29)

1. Wong WM, Gu Q, Chu KM, et al. Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2006;23:421-427.
2. Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996;110:1244-1252.
3. Zullo A, De Francesco V, Manes G, Scaccianoce G, Cristofari F, Hassan C. Second-line and rescue therapies for Helicobacter pylori eradication in clinical practice. J Gastrointestin Liver Dis 2010;19:131-134.
4. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-781.
5. Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009;24:1587-1600.
6. Gisbert JP, González L, Calvet X, et al. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther 2000;14:1319-1328.
7. Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007;147:553-562.
8. Lee JH, Hong SP, Kwon CI, et al. The efficacy of levofloxacin based triple therapy for Helicobacter pylori eradication. Korean J Gastroenterol 2006;48:19-24.
9. Lamouliatte H, Samoyeau R, De Mascarel A, Megraud F. Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 1999;13:1523-1530.
10. Wurzer H, Rodrigo L, Stamler D, et al. Short-course therapy with amoxycillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer. ACT-10 Study Group. Aliment Pharmacol Ther 1997;11:943-952.
11. Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998;13:1-12.
12. Gisbert JP, Pajares JM. Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002;16:1047-1057.
13. Kim SY, Jung SW. Helicobacter pylori eradication therapy in Korea. Korean J Gastroenterol 2011;58:67-73.
14. Gisbert JP. Second-line rescue therapy of helicobacter pylori infection. Therap Adv Gastroenterol 2009;2:331-356.
15. Li Y, Huang X, Yao L, Shi R, Zhang G. Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis. Wien Klin Wochenschr 2010;122:413-422.
16. Watanabe Y, Aoyama N, Shirasaka D, et al. Levofloxacin based triple therapy as a second-line treatment after failure of helicobacter pylori eradication with standard triple therapy. Dig Liver Dis 2003;35:711-715.
17. Di Caro S, Zocco MA, Cremonini F, et al. Levofloxacin based regimens for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 2002;14:1309-1312.
18. Gisbert JP, Gisbert JL, Marcos S, Jimenez-Alonso I, Moreno-Otero R, Pajares JM. Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients. Aliment Pharmacol Ther 2008;27:346-354.
19. Bilardi C, Dulbecco P, Zentilin P, et al. A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial. Clin Gastroenterol Hepatol 2004;2:997-1002.
20. Matsumoto Y, Miki I, Aoyama N, et al. Levofloxacin- versus metronidazole-based rescue therapy for H. pylori infection in Japan. Dig Liver Dis 2005;37:821-825.
21. Di Caro S, Franceschi F, Mariani A, et al. Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication. Dig Liver Dis 2009;41:480-485.
22. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006;23:35-44.
23. Kuo CH, Hu HM, Kuo FC, et al. Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial. J Antimicrob Chemother 2009;63:1017-1024.
24. Nista EC, Candelli M, Cremonini F, et al. Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther 2003;18:627-633.
25. Kim N, Kim JM, Kim CH, et al. Institutional difference of antibiotic resistance of Helicobacter pylori strains in Korea. J Clin Gastroenterol 2006;40:683-687.
26. Kim JY, Kim NY, Kim SJ, et al. Regional difference of antibiotic resistance of helicobacter pylori strains in Korea. Korean J Gastroenterol 2011;57:221-229.
27. Gerrits MM, van der Wouden EJ, Bax DA, et al. Role of the rdxA and frxA genes in oxygen-dependent metronidazole resistance of Helicobacter pylori. J Med Microbiol 2004;53(Pt 11):1123-1128.
28. Kim JY, Kim N, Park HK, et al. Primary antibiotic resistance of Helicobacter pylori strains and eradication rate according to gastroduodenal disease in Korea. Korean J Gastroenterol 2011;58:74-81.
29. Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pyori infection: a meta-analysis. Am J Gastroenterol 2006;101:488-496.